Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial
Abstract Background MYC genes regulate ornithine decarboxylase (Odc) to increase intratumoral polyamines. We conducted a Phase I trial [NCT02030964] to determine the maximum tolerated dose (MTD) of DFMO, an Odc inhibitor, with celecoxib, cyclophosphamide and topotecan. Methods Patients 2–30 years of...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 语言: | 英语 |
| 出版: |
2024
|
| 在线阅读: | https://doi.org/10.1038/s41416-023-02525-2 https://www.nature.com/articles/s41416-023-02525-2.pdf |
| 标签: |
添加标签
没有标签, 成为第一个标记此记录!
|